Wird geladen...
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
BACKGROUND: Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patient...
Gespeichert in:
| Veröffentlicht in: | BMC Cancer |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4810513/ https://ncbi.nlm.nih.gov/pubmed/27026229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2282-5 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|